PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SCHOFIELD, Wis., May 30, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.

Highlights of the almost seven-minute interview, include:

  • Revenue Potential for LipiGesic® M Could Exceed $50 Million
  • Expanding Retail Chain-Store Distribution
  • Expansion into International Markets
  • Potential Patent Portfolio Acquisition Worth Millions
  • Market Capitalization Currently under $1 Million

Revenue Potential
Russ Mitchell, the Chairman and CEO of PuraMed BioScience, commented that with nearly 60 million Americans suffering from migraines the revenue potential for LipiGesic M, their over-the-counter migraine pain relief product, could generate over $50 million in sales annually by capturing just 1 percent of the migraine market.

Mr. Mitchell also discussed expanding distribution for their over-the-counter migraine pain reliever product, LipiGesic M, which is currently available in approximately 15,000 Walgreen's and CVS/pharmacy stores in all 50 states in the United States. According to Mr.Mitchell, he expects LipiGesic M to expand distribution into additional chains and wholesalers including all major retailers known to carry health and beauty products.

Off air, Mr. Mitchell said, "This expanded distribution would include mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains, which would add approximately another 21,000 stores."

In addition to US distribution, PuraMed BioScience has received its initial order from Columbia and has plans to expand to other Latin American countries as well as other regions around the world.

Patent Portfolio Acquisition
In the interview, Mr. Mitchell discussed current negotiations to acquire a patent portfolio of products in the anti-inflammatory, anti-bacterial, and anti-viral categories. Upon completion of the acquisition, PuraMed BioScience intends to license some of these patents to larger key manufacturers or bring these products to market directly. Mr. Mitchell commented, "Each one of those categories is huge, and has the potential to bring in many millions of dollars of additional revenue as these products get placed into the market."

To access the online interview please visit http://www.wallstreetnewscast.com/profile/pmbs.html

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, www.lipiGesic.com, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Melissa Diaz,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com

SOURCE PuraMed BioScience, Inc.



Help employers find you! Check out all the jobs and post your resume.

Back to news